Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $298.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target hoisted by Raymond James from $275.00 to $298.00 in a research report released on Friday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on ALNY. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. TD Cowen upped their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Barclays increased their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday. Scotiabank boosted their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday. Finally, Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $294.50.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $273.91 on Friday. The stock’s 50 day simple moving average is $274.61 and its 200-day simple moving average is $226.42. The company has a market cap of $35.16 billion, a PE ratio of -104.55 and a beta of 0.39. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the firm earned $1.15 EPS. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -2.74 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $26,000. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $29,000. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals during the first quarter worth approximately $30,000. Finally, Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $42,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.